Inactive Instrument

Intersect ENT, Inc.

Equities

XENT

US46071F1030

Medical Equipment, Supplies & Distribution

Intersect ENT, Inc. Announces Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2014

January 13, 2015 at 02:35 am IST

Intersect ENT, Inc. announced preliminary unaudited financial guidance for the fourth quarter and year ended December 31, 2014. For the quarter, the company expected to report revenue in the range of $13.2 to $13.4 million, an increase of approximately 91% over the fourth quarter of 2013.

For the year end, the company expects to report revenue in the range of $38.4 to $38.6 million.

Latest news about Intersect ENT, Inc.

Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P Healthcare Equipment Select Industry Index	17/22/17	CI
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P TMI Index	17/22/17	CI
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from S&P Global BMI Index	17/22/17	CI
Medtronic Completes Purchase Of US Medical Device Group Intersect ENT	13/22/13	MT
Medtronic Completes Purchase of Intersect ENT	13/22/13	MT
Intersect ENT, Inc.(NasdaqGM:XENT) dropped from NASDAQ Composite Index	13/22/13	CI
Hemostasis, LLC acquired Fiagon AG Medical Technologies from Intersect ENT, Inc.	13/22/13	CI
Medtronic plc completed the acquisition of Intersect ENT, Inc..	13/22/13	CI
Intersect ENT, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	05/22/05	CI
Intersect ENT, Inc. Enters into Amendment No.1 to Facility Agreement	19/22/19	CI
Intersect ENT, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	09/22/09	CI
Intersect ENT Reports Positive Data From Real-World Evidence Study of Propel Sinus Implants	25/22/25	MT
Intersect ENT®, Inc. Announces Positive Results of Observational	25/22/25	CI
Berenberg Bank Terminates Coverage on a Number of Companies Due to Analysts' Departures From the Firm	13/21/13	MT
Intersect ENT, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	03/21/03	CI
Earnings Flash (XENT) INTERSECT ENT Reports Q3 Loss $-0.48	03/21/03	MT
Earnings Flash (XENT) INTERSECT ENT Posts Q3 Revenue $24.4M	03/21/03	MT
Transcript : Intersect ENT, Inc. - Shareholder/Analyst Call	08/21/08
Intersect ENT, Inc. Enters into Facility Agreement	28/21/28	CI
North American Morning Briefing : Blockbuster -3-	13/21/13	DJ
INTERSECT ENT : SVB Leerink Downgrades Intersect ENT to Market Perform From Outperform; Price Target is $28.25	12/21/12	MT
North American Morning Briefing : Investors Await -3-	11/21/11	DJ
INTERSECT ENT : BTIG Downgrades Intersect ENT to Neutral From Buy	10/21/10	MT
INTERSECT ENT : Canaccord Genuity Downgrades Intersect ENT to Hold from Buy, Adjusts Price Target to $28.25 from $29	09/21/09	MT
INTERSECT ENT : Berenberg Bank Adjusts Intersect ENT Price Target to $28.25 From $18, Maintains Hold Rating	09/21/09	MT

Chart Intersect ENT, Inc.

Duration

Period

More charts

Company Profile

Intersect ENT, Inc. is a global ear, nose, and throat (ENT) medical technology company. The Company's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. It also offers ENT products, such as VenSure and CUBE.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-5.60%	181B
MEDTRONIC PLC	-4.45%	101B
BECTON, DICKINSON AND COMPANY	-4.15%	67.54B
DEXCOM, INC.	-8.63%	45.09B
CENCORA, INC.	+9.70%	44.37B
HOYA CORPORATION	+6.13%	40.7B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	29.85B
TERUMO CORPORATION	+14.80%	24.49B
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.99B

Other Medical Equipment, Supplies & Distribution